Homology Medicines Stock Price, News & Analysis (NASDAQ:FIXX)

$20.98
+0.58 (+2.84 %)
(As of 09/20/2019 04:00 PM ET)
Today's Range
$20.30
Now: $20.98
$21.00
50-Day Range
$14.56
MA: $18.34
$21.56
52-Week Range
$14.19
Now: $20.98
$31.80
Volume217,013 shs
Average Volume227,591 shs
Market Capitalization$922.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
CUSIPN/A
Phone781-301-7277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.68 million
Book Value$5.19 per share

Profitability

Net Income$-57,220,000.00
Net Margins-3,232.67%

Miscellaneous

Employees124
Market Cap$922.49 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.


Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) announced its earnings results on Thursday, August, 8th. The company reported ($0.61) EPS for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.06. The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $1 million. Homology Medicines had a negative net margin of 3,232.67% and a negative return on equity of 38.74%. View Homology Medicines' Earnings History.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Homology Medicines.

What price target have analysts set for FIXX?

4 brokerages have issued 1 year price targets for Homology Medicines' stock. Their forecasts range from $29.00 to $37.00. On average, they expect Homology Medicines' stock price to reach $33.00 in the next year. This suggests a possible upside of 57.3% from the stock's current price. View Analyst Price Targets for Homology Medicines.

What is the consensus analysts' recommendation for Homology Medicines?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Has Homology Medicines been receiving favorable news coverage?

Headlines about FIXX stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Homology Medicines earned a coverage optimism score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Homology Medicines.

Are investors shorting Homology Medicines?

Homology Medicines saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 3,618,500 shares, an increase of 13.5% from the July 31st total of 3,188,800 shares. Based on an average daily volume of 274,600 shares, the short-interest ratio is currently 13.2 days. Currently, 12.9% of the company's stock are short sold. View Homology Medicines' Current Options Chain.

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Stag Industrial (STAG), Micron Technology (MU), NVIDIA (NVDA), Snap (SNAP), Exelixis (EXEL), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH) and Intel (INTC).

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the folowing people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 56)
  • Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 50)
  • Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 63)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.74%), JPMorgan Chase & Co. (4.60%), Price T Rowe Associates Inc. MD (4.45%), Vanguard Group Inc. (2.33%), Rock Springs Capital Management LP (0.97%) and Cormorant Asset Management LP (0.69%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am, Vida Ventures, Llc and W Bradford Smith. View Institutional Ownership Trends for Homology Medicines.

Which major investors are selling Homology Medicines stock?

FIXX stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P. and BNP Paribas Arbitrage SA. Company insiders that have sold Homology Medicines company stock in the last year include Albert Seymour, Arthur Tzianabos, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am and W Bradford Smith. View Insider Buying and Selling for Homology Medicines.

Which major investors are buying Homology Medicines stock?

FIXX stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BlackRock Inc., Vanguard Group Inc., Cormorant Asset Management LP, Point72 Asset Management L.P., Nuveen Asset Management LLC, Charles Schwab Investment Management Inc. and Northern Trust Corp. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $20.98.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $922.49 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.View Additional Information About Homology Medicines.

What is Homology Medicines' official website?

The official website for Homology Medicines is http://www.homologymedicines.com/.

How can I contact Homology Medicines?

Homology Medicines' mailing address is One Patriots Park, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.


MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  63 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  126
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel